Single-Cell Sequencing: The Tech Unlocking Cancer’s Stubborn Cells скачать в хорошем качестве

Single-Cell Sequencing: The Tech Unlocking Cancer’s Stubborn Cells

Welcome to episode 3 of the PERSIST-SEQ video series, where we take you behind the scenes of cutting edge-research into treatment-resistant cancers. In this episode, we speak with Alexander van Oudenaarden from the Hubrecht Institute, a key partner in this EU-funded consortium. In this video, you’ll hear about: 🧫 How single-cell sequencing helps detect the rare cancer cells that survive treatment 🧫 Why standardised methods across labs are key to understanding cancer 🧫 How collaboration between academia, biotech startups, and pharma accelerates cancer research What is PERSIST-SEQ? PERSIST-SEQ is an Innovative Medicines Initiative 2 project. This public-private partnership investigates why and how tumours persist. By using single-cell sequencing, patient-derived organoids and xenografts, researchers across Europe aim to create reproducible workflows for studying tumour persistence. The consortium focuses on understanding tumour plasticity, particularly drug-tolerant persister cells. To learn more about PERSIST-SEQ: Head to our website https://persist-seq.org/ Find us on LinkedIn https://www.linkedin.com/shareArticle... If you have any questions about PERSIST-SEQ, please contact the PERSIST-SEQ secretariat: info@persist-seq.org 🧑‍🔬Who is this video for? 🧬Cancer researchers and clinicians 🧬 Policy makers, regulators and healthcare innovators 🧬 Patients, advocates, and curious members of the public Keywords: Cancer research, oncology, therapeutic resistance, drug resistance, single cell sequencing, spatial transcriptomics, open science, patient derived organoids, patient derived xenografts, collaboration, personalised medicine, science communication #cancer #research #oncology Credits and acknowledgements: Thanks to videographer Esther Pardijs for the b-roll clips used with permission from Hubrecht Institute